The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety and efficacy of pemigatinib plus pembrolizumab combination therapy in patients (pts) with advanced malignancies: Results from FIGHT-101, an open-label phase I/II study.
 
Martin Gutierrez
Stock and Other Ownership Interests - Cota Healthcare
Honoraria - Foundation Medicine; Guardant Health
Consulting or Advisory Role - Exenex
Speakers' Bureau - Bristol-Myers Squibb; Lilly; Merck
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Checkpoint Therapeutics (Inst); Eisai (Inst); GSB Pharma (Inst); Incyte (Inst); Johnson & Johnson (Inst); MedImmune (Inst); Merck (Inst); Moderna Therapeutics (Inst); NextCure (Inst); Pfizer (Inst); Regeneron (Inst); Roche/Genentech (Inst); Sanofi (Inst); Seagen (Inst); Silenseed (Inst)
Travel, Accommodations, Expenses - Guardant Health
 
Vivek Subbiah
Consulting or Advisory Role - Helsinn Therapeutics; Loxo; MedImmune; QED Therapeutics; R-Pharm
Research Funding - Abbvie (Inst); Agensys (Inst); Alfasigma (Inst); Amgen (Inst); Amgen (Inst); Bayer (Inst); Berg Pharma (Inst); Blueprint Medicines (Inst); Boston Biomedical (Inst); D3 Oncology Solutions (Inst); Exelixis (Inst); Fujifilm (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Idera (Inst); Incyte (Inst); Inhibrx (Inst); LOXO (Inst); Multivir (Inst); NanoCarrier (Inst); Northwest Biotherapeutics (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Takeda (Inst); Turning Point Therapeutics (Inst); Vegenics (Inst)
Travel, Accommodations, Expenses - Bayer; Helsinn Therapeutics; Novartis; PharmaMar
Other Relationship - Medscape
 
John J. Nemunaitis
Employment - Gradalis
Leadership - Gradalis
Stock and Other Ownership Interests - Gradalis
Honoraria - AstraZeneca
Consulting or Advisory Role - SymVivo
Speakers' Bureau - AstraZeneca
Patents, Royalties, Other Intellectual Property - Gradalis
Expert Testimony - Foundation Medicine
 
Niharika B. Mettu
No Relationships to Disclose
 
Kyriakos P. Papadopoulos
Consulting or Advisory Role - ArQule; Bayer
Research Funding - 3D Medicines (Inst); Abbvie (Inst); ADC Therapeutics (Inst); Amgen (Inst); ARMO BioSciences (Inst); ArQule (Inst); Bayer (Inst); Calithera Biosciences (Inst); Curegenix (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Formation Biologics (Inst); Incyte (Inst); Jounce Therapeutics (Inst); MabSpace Biosciences (Inst); MedImmune (Inst); Merck (Inst); Mersana (Inst); OncoMed (Inst); Peloton Therapeutics (Inst); Regeneron (Inst); Sanofi (Inst); Syros Pharmaceuticals (Inst)
 
Minal A. Barve
No Relationships to Disclose
 
Luis Féliz
Employment - Incyte
Stock and Other Ownership Interests - Incyte
 
Christine Francis Lihou
Employment - Incyte
Stock and Other Ownership Interests - Incyte
 
Chenwei Tian
Employment - Incyte
Stock and Other Ownership Interests - I-Mab
 
Tao Ji
Employment - Incyte
Stock and Other Ownership Interests - Incyte
 
Ian M. Silverman
Employment - Incyte
Stock and Other Ownership Interests - Incyte
 
Rashmi Chugh
Consulting or Advisory Role - Immune Design
Research Funding - AADi (Inst); Advenchen Laboratories (Inst); Epizyme (Inst); Lilly (Inst); MabVax (Inst); Morphotek (Inst); Mundipharma (Inst); Novartis (Inst); Pfizer (Inst); Plexxikon (Inst); SpringWorks Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Wolters Kluwer
Travel, Accommodations, Expenses - SpringWorks Therapeutics
 
Mansoor N. Saleh
Honoraria - Genentech
Speakers' Bureau - Gilead Sciences; Novartis
Research Funding - Aileron Therapeutics (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Lilly (Inst)